Serum calcitonin precursors in sepsis and systemic inflammation
- PMID: 9745444
- DOI: 10.1210/jcem.83.9.5129
Serum calcitonin precursors in sepsis and systemic inflammation
Abstract
High serum levels of the calcitonin (CT) prohormone, procalcitonin (pro-CT), and its component peptides occur in systemic inflammation and sepsis. Using two different assays, we undertook a prospective study to determine the utility of serum precalcitonin peptides (pre-CT) as markers in this condition. Twenty-nine patients meeting criteria for the systemic inflammatory response syndrome were studied daily in two intensive care units. Sera were collected, and APACHE II scores were determined until recovery or death. All patients had markedly elevated serum pre-CT. Prognostically, peak values were the most important. The highest values portended mortality, and a lower level could be ascertained below which all patients survived. Peak pre-CT levels were significantly higher in patients with infection documented by blood cultures than in those patients with no documented infection from any source (P < 0.05). Mature CT remained normal or only moderately elevated. Compared with the serum pre-CT levels, receiver operating characteristic curve analysis revealed that the APACHE II scores, although more cumbersome, were better overall predictors of mortality. Thus, pre-CT is an important serum marker for systemic inflammatory response syndrome and is predictive of outcome. It also provides data concerning the presence of severe infection and may prove to be clinically useful for proactive patient care.
Similar articles
-
Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.Br J Pharmacol. 2010 Jan 1;159(2):253-64. doi: 10.1111/j.1476-5381.2009.00433.x. Epub 2009 Nov 27. Br J Pharmacol. 2010. PMID: 20002097 Free PMC article. Review.
-
Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization.J Investig Med. 1997 Dec;45(9):552-60. J Investig Med. 1997. PMID: 9444882
-
Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.J Intern Med. 2014 Dec;276(6):651-8. doi: 10.1111/joim.12238. Epub 2014 Apr 8. J Intern Med. 2014. PMID: 24645798
-
Procalcitonin levels in surgical patients at risk of candidemia.J Infect. 2010 Jun;60(6):425-30. doi: 10.1016/j.jinf.2010.03.003. Epub 2010 Mar 10. J Infect. 2010. PMID: 20226210
-
Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations.Crit Care Med. 2008 Mar;36(3):941-52. doi: 10.1097/CCM.0B013E318165BABB. Crit Care Med. 2008. PMID: 18431284 Review.
Cited by
-
Prognostic Value of Serum Procalcitonin Based Model in Moderate to Severe Traumatic Brain Injury Patients.J Inflamm Res. 2022 Aug 30;15:4981-4993. doi: 10.2147/JIR.S358621. eCollection 2022. J Inflamm Res. 2022. PMID: 36065318 Free PMC article.
-
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335. Thyroid. 2015. PMID: 25810047 Free PMC article. Review.
-
Procalcitonin in preoperative diagnosis of abdominal sepsis.Langenbecks Arch Surg. 2008 May;393(3):397-403. doi: 10.1007/s00423-007-0239-5. Epub 2007 Oct 30. Langenbecks Arch Surg. 2008. PMID: 17968584
-
Postmortem chemistry update part II.Int J Legal Med. 2012 Mar;126(2):199-215. doi: 10.1007/s00414-011-0614-1. Epub 2011 Oct 9. Int J Legal Med. 2012. PMID: 21984165 Review.
-
Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.Br J Pharmacol. 2010 Jan 1;159(2):253-64. doi: 10.1111/j.1476-5381.2009.00433.x. Epub 2009 Nov 27. Br J Pharmacol. 2010. PMID: 20002097 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources